This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Illumina Is How You Play Biotech Without Being in Biotech

NEW YORK (TheStreet) -- Biotech stocks are volatile and investors have a tendency to trade the whole group together. However, there are opportunities to be found. One is Illumina (ILMN - Get Report), which is not a biotech but works with the biotech industry.

Illumina was founded in 1998 in San Diego and develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Illumina has grown tremendously over the last few years and now employs 3,100+ people worldwide. Last year the company generated $1.42 billion in revenue.

One of the things I like about the Illumina story is it is not dependent on a particular drug or customer.

Looking at Ilumina's stock chart, you can see that after a selloff from March to April, Illumina has come roaring back and is now up 50% for the year. The stock has been trading well since the end of April when it reported a solid quarter, beating earnings estimates by $0.02 and exceeding revenue estimates with management guiding up both earnings and revenue estimates. First-quarter revenue increased an impressive 27% on a year-over-year basis.

ILMN Chart
data by YCharts

Illumina's products are selling well in the marketplace and its HiSeq X Ten low-cost ($1,000), ultra-high-throughput sequencer product is gaining traction even faster than anticipated. The product just starting shipping in Q1 of this year and already received orders for 104 units during the quarter. Illumina's large portfolio of sequencers and market penetration has created a barrier to entry for new competitors.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ILMN $138.70 0.00%
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%
TSLA $150.20 4.50%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs